Thesis: Illumina is the profitable DNA-sequencing turnaround — GAAP-positive and cash-generative, re-rated +80%/1y into a golden-cross uptrend as a top-10 IBB weight — but the top line is barely growing (+4.8% YoY), so own it as a margin/turnaround hold on a pullback to the SMA20, not as a chase at RSI 70.

Verdict: Trend-hold-eligible, conviction medium. ILMN passes our confirmation filter cleanly — GAAP-profitable, strong-up, golden cross active, +40% above the SMA200, and only −0.95% off its 52-week high — so it is a genuine recovered uptrend, not a falling knife. The cap is twofold: growth is anemic (+4.8% YoY, revenue-growth read bearish), making this a margin/turnaround story rather than secular compounding; and the tape is extended near-term (+9% above SMA20, +21% above SMA50, RSI 70). Don't chase the extension. Add on a pullback toward the rising SMA20 ($166); a clean break below the SMA50 ($150) voids the structure. Distinguish the business (profitable, cash-rich — good) from its growth (slow — the ceiling).

The Story Right Now

Illumina is the dominant DNA-sequencing platform — instruments plus the recurring consumables that run on them — and it is now past the GRAIL acquisition/divestiture and activist saga that gutted the stock. The other side of that saga is a company back to GAAP profitability and strong cash generation, and the tape has noticed: +49.9% over three months, +79.66% over the trailing year, and within −0.95% of the 52-week high.

The setup sits inside a broader breadth story. From the IBB breadth-decomposition investigation, the iShares Nasdaq Biotechnology fund is at an all-time high carried by mid-cap and genomics names while the mega-cap anchors (GILD, REGN, ALNY) lag. ILMN is both a top-10 IBB weight (~2.2%) and one of its three-month leaders, so it is participating in the move that is actually driving the index, not free-riding on it. It sits in our ibb and biotech-scan watchlists.

The catch is the engine underneath. Quarterly revenue is running roughly flat-to-low-growth (~$1.06–1.09B/qtr), and the leading-indicator composite is Neutral (0.1): revenue growth reads bearish at +4.8% YoY, while the earnings signal is strong with a 100% beat rate. That split is the whole thesis — the profit and cash story is real, the growth story is not. So this is a re-rate on margins and operating leverage, and it should be held as such.

Setup

• Entry zone: Buy a pullback toward the rising SMA20 (~$166). At $181.10 the price is +8.9% above the SMA20 and +20.8% above the SMA50 — extended near-term, with RSI at 70. Wait for the dip rather than chasing the high.
• Stop: Below the SMA50 (~$149.97). A clean break there voids the recovery-trend structure and turns this back into a falling-knife setup we don't hold.
• Target: Prior highs and trend continuation while the margin/turnaround story holds. Trail the stop up under the SMA20/SMA50 rather than naming a fixed price target.
• Conviction: Medium. Confirmation is clean, but the anemic top line and the extended position above the averages both cap it.
• Sizing: Starter-to-half on a confirmed pullback to the SMA20; this is a turnaround hold, not a high-conviction grower, so it does not earn a full-size allocation. Don't average down through the SMA50 stop.

Bull case

• Genuinely profitable now. FY2025 delivered +$850M net income, +$5.45 diluted EPS, +$807M operating income, and +$1.08B operating cash flow — the turnaround is in the financials, not just the chart.
• Confirmed uptrend. Strong-up trend, golden cross active, +40.4% above the SMA200, and −0.95% off the 52-week high. By our trend-hold filter this is a recovered secular leader, not a bounce.
• Index leadership with breadth behind it. A top-10 IBB weight (~2.2%) and a three-month leader inside an index making all-time highs on exactly the mid-cap/genomics breadth ILMN belongs to — the move has support under it.
• Earnings momentum. The leading-indicator earnings signal is strong with a 100% beat rate; the next quarterly report has a good track record behind it.
• Platform moat + cash. Dominant installed base of sequencers with recurring consumables pull-through; the operating-leverage story has room to run as the post-GRAIL cost structure normalizes.

Bear case

• Growth is anemic. +4.8% revenue YoY with quarterly revenue roughly flat (~$1.06–1.09B/qtr). The leading-indicator revenue-growth read is bearish — this is the single biggest cap on conviction.
• Extended near-term. +8.9% above SMA20, +20.8% above SMA50, RSI 70. Chasing here invites a mean-reversion drawdown back toward the averages.
• Margin story, not a grower. The re-rate is built on profitability recovery, not top-line acceleration; if margin gains plateau before revenue inflects, the multiple has little to lean on.
• Composite is only Neutral. The leading-indicator composite sits at 0.1 — no strong forward tailwind, with insider trading also Neutral.
• Thin near-cash cushion. Short-term investments were only $66M at 2026-03-29; the cash-flow story carries the balance sheet, so any operating wobble shows up fast.

Catalysts

• Next quarterly report. Watch the revenue line for any move off the +4.8% YoY pace — a revenue inflection is what would lift this from a margin/turnaround hold toward a grower. The earnings track record is strong (100% beat rate); the open question is the top line, not the bottom line.
• The next readout on consumables pull-through and instrument placements — the leading indicator of whether the installed base is driving recurring growth.
• Margin / operating-leverage trajectory — continued operating-income expansion sustains the re-rate; a stall removes the prop.
• IBB breadth regime. As a top-10 weight, ILMN is exposed to the mid-cap/genomics breadth currently carrying the index; a rotation back toward the lagging mega-cap anchors would pull a tailwind out from under it.
• Tape trigger: a pullback toward the rising SMA20 ($166) is the entry signal; a clean break of the SMA50 ($150) is the exit signal.

Financials

Leading-indicator read (leading ILMN): the composite is Neutral at 0.1. The earnings signal is strong with a 100% beat rate, but revenue growth is bearish — only +4.8% YoY — and insider trading is Neutral. That divergence is the core of the framing: the profit/cash side is healthy while the growth side is not, which is why this reads as a margin/turnaround name rather than a secular grower.

Balance-sheet / FCF note: ILMN is now self-funding off operations — FY2025 operating cash flow of +$1.08B against +$850M net income shows clean cash conversion, and that cash generation, not a large near-cash buffer ($66M short-term investments at 2026-03-29), is what underwrites the recovery. The implication for sizing: the story is durable as long as operating cash flow holds, but there is little balance-sheet slack to absorb a growth or margin stumble, which keeps conviction at medium.

Cross-references

• The June 29 IBB breadth-decomposition investigation — IBB at all-time highs on mid-cap/genomics breadth; ILMN as top-10 weight (~2.2%) and three-month leader while GILD/REGN/ALNY lag.
• Watchlists: ibb, biotech-scan.
• Trend-hold lens: confirmed-uptrend, buy-the-pullback discipline this setup is filtered against.

Sources

• Price truth (settled Fri 2026-06-26 close): internal pre-computed summaries, summaries — $181.10, RSI 70, strong-up, golden cross active; SMA20 $166.24, SMA50 $149.97, SMA200 $128.97; 30d +10.16%, 3m +49.9%, 1y +79.66%, −0.95% off 52-week high; VWAP $123.56, relVol 0.65.
• Financials: SEC EDGAR XBRL via the desk's own tooling — FY2025 and Q1 FY26 revenue, operating income, net income, EPS, operating cash flow, and short-term investments as tabled above.
• Leading indicators: leading ILMN — composite Neutral (0.1), revenue growth bearish (+4.8% YoY), earnings strong (100% beat rate), insider trading Neutral.
• Breadth context: 2026-06-29-ibb-at-all-time-highs-breadth-decomposition-of-the-ishares-nasdaq-biotechnology-.